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Abstract
Background We aimed to examine the relationship between musculoskeletal deterioration and all-cause mortality in a
cohort of women studied prospectively over a decade.
Methods A cohort of 750 women aged 50–94 years was followed for a decade after femoral neck bone mineral density
(BMD) and appendicular lean mass (ALM) were measured using dual energy X-ray absorptiometry, in conjunction with comor-
bidities, health behaviour data, and other clinical measures. The outcome was all-cause mortality identiﬁed from the
Australian National Deaths Index. Using Cox proportional hazards models and age as the time variable, mortality risks were
estimated according to BMD groups (ideal-BMD, osteopenia, and osteoporosis) and ALM groups (T-scores>1.0 high,
2.0 to 1.0 medium, <2.0 low).
Results During 6712 person years of follow-up, there were 190 deaths, the proportions increasing with diminishing BMD:
10.7% (23/215) ideal-BMD, 23.5% (89/378) osteopenia, 49.7% (78/157) osteoporosis; and with diminishing ALM: 17.0%
(59/345) high, 26.2% (79/301) medium, 50.0% (52/104) low. In multivariable models adjusted for smoking, polypharmacy,
and mobility, compared with those with ideal BMD, mortality risk was greater for those with osteopenia [hazard ratio
(HR) 1.77, 95% conﬁdence interval (CI) 1.11–2.81] and osteoporosis (HR 2.61, 95%CI 1.60–4.24). Similarly, compared with
those with high ALM, adjusted mortality risk was greater for medium ALM (HR 1.36, 95%CI 0.97–1.91) and low ALM
(HR 1.65, 95%CI 1.11–2.45). When BMD and ALM groups were tested together in the model, BMD remained a predictor
of mortality (HR 1.74, 95%CI 1.09–2.78; HR 2.82, 95%CI 1.70–4.70; respectively), and low ALM had borderline signiﬁcance
(HR 1.52, 95%CI 1.00–2.31), which was further attenuated after adjusting for smoking, polypharmacy, and mobility.
Conclusions Poor musculoskeletal health increased the risk for mortality independent of age. This appears to be driven
mainly by a decline in bone mass. Low lean mass independently exacerbated mortality risk, and this appeared to operate
through poor health exposures.
Keywords Dual energy X-ray absorptiometry; Lean mass; Mortality risk; Musculoskeletal health; Osteoporosis; Osteosarcopenia;
Sarcopenia
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Introduction
As the population ages, more attention is being focussed on
delaying morbidity. The cumulative effect of multiple morbid-
ities over a lifetime manifests as frailty, loss of independence,
and diminished quality of life. Musculoskeletal decline is an
important feature of frailty.1 An age-related decline in
musculoskeletal health is well documented, particularly for
bone,2,3 with more recent attention directed towards the
decline in skeletal muscle mass and function.4–7 Associations
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between decreased bone mineral density (BMD),8–10 acceler-
ated bone loss,11 fracture,12 and mortality have been
described. Measures of skeletal muscle mass including mid-
arm muscle circumference,13,14 lean mass by bioelectrical
impedance analysis (BIA),15–18 and appendicular lean muscle
mass by dual energy X-ray absorptiometry (DXA)17 report
an inverse relationship with premature mortality. However,
some studies that have assessed lean mass by BIA14 and calf
muscle density and muscle area by peripheral quantitative
computed tomography19 have not observed such a
relationship.
While the evidence supports an association between
skeletal deterioration and mortality risk, the association is
uncertain for low skeletal muscle mass. Whether skeletal
deterioration and low skeletal muscle mass act alone or in
combination to determine mortality risk is unclear. The ratio-
nale for investigating mortality risk in association with
components of musculoskeletal deterioration rests with the
notion of a bone-muscle coupling20,21 that is underpinned
by cross-talk between bone and muscle involving mechanical
and hormonal stimuli22–24; this notion is supported by
observed associations between bone mass and muscle
mass.25,26 Therefore, we aimed to examine the relationship
between the components of musculoskeletal deterioration
and all-cause mortality in a cohort of women studied pro-
spectively over a decade.
Methods
Subjects
An age-stratiﬁed sample of 1494 women was selected at
random from electoral rolls for the Barwon Statistical
Division, a geographically distinct area surrounding the
regional city of Geelong in south-eastern Australia, for
participation in the Geelong Osteoporosis Study.27 Registra-
tion on Australian electoral rolls is compulsory, providing a
complete listing of the adult population. Women aged
20 years and over were enrolled 1993–1997, with a partici-
pation of 77.1%. Details of non-participation have been
described elsewhere.28 For this study, we included only
women aged 50 years and over. Of the potential 837
women, 87 were excluded because measures of lean mass
were unavailable for analysis including 15 with bilateral
prostheses. Thus, 750 women with a median age of
70.5 years (range 50–92) were eligible for the analysis.
Written, informed consent was obtained from all partici-
pants. This study was approved by the Barwon Health
Human Research Ethics Committee and has therefore been
performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki and its later
amendments.
Measurements
The outcome was all-cause mortality, determined by data
linkage of our database with the Australian National Deaths
Index. All exposure data were recorded at baseline. Height
and weight were measured to the nearest 0.001m and
0.1 kg, respectively, and body mass index calculated in
kg/m2. Body composition was assessed by DXA using a
Lunar densitometer (Lunar DPX-L, Madison, WI, USA)
thereby providing measures of lean tissue mass and BMD.
Lean tissue assessed by whole body DXA technology
comprises non-fat and non-bone tissue and compares well
with skeletal muscle mass measured using magnetic reso-
nance imaging.29 Appendicular lean mass (ALM) (kg) was
determined by summing lean mass measures for the arms
and legs. Low ALM was recognized for T-scores<2.0
(low, equivalent to the cut-point used to identify
sarcopenia) and 2.0 to 1.0 (medium, equivalent to
pre-sarcopenia); ideal lean mass (high) was equivalent to
ALM T-score>1.0.4 For individuals who had incomplete
scans (n = 100) or were affected by prostheses one side of
the body (n = 14), ALM measures were derived by doubling
values for the unaffected side of the body. BMD measures
of the femoral neck were used to identify osteoporosis
(T-score<2.5) and osteopenia (T-score 2.5 to 1.0)
and ideal BMD (T-score>1.0).2
Self-reported details of medication use and health
behaviours were documented by questionnaire. Mobility
was categorized as very active, active, sedentary, limited,
inactive, or chair/bed ridden (descriptors were included in
the questionnaire27 but are not shown here), and for this
analysis, these categories were collapsed into three groups
of active (includes very active), sedentary, and inactive
(includes the other categories). Tobacco smoking was
identiﬁed as current, past, or never. Alcohol use was
recorded as either never, less than once a week, once or
twice a week, several times a week, or every day.
Polypharmacy referred to the number of prescription
medications used regularly; they were categorized into
groups of three or more for descriptive purposes. Expo-
sures to disease states were self-reported and grouped into
cardiovascular disease, neurological disorders, endocrine
disorders, lung diseases, gastrointestinal disorders, malig-
nancies, and ‘other’ disorders that were not classiﬁed
elsewhere (including kidney stones, pernicious anaemia,
cirrhosis of the liver, liver failure, kidney failure, and ne-
phrotic syndrome). Socio-economic status was ascertained
using Socio-Economic Index for Areas index scores based
on census data from the Australian Bureau of Statistics
(1996). These data were used to derive an Index of
Relative Socio-Economic Disadvantage that was catego-
rized into ﬁve groups, according to quintiles of Index of
Relative Socio-Economic Disadvantage for the study
region.
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Statistics
Collection of BMD, ALM, and other clinical measures, to-
gether with questionnaire data, was performed concurrently
at baseline. To test for differences in subject characteristics
according to categories of BMD or ALM, we used one-way
analysis of variance for continuous data that were normally
distributed, a Kruskal–Wallis test for continuous non-
parametric data and a Chi-squared test for categorical data.
Subjects were followed longitudinally from baseline for
10 years or until the date of death, whichever occurred ﬁrst.
Overall survival was compared between the three BMD groups
(or the three ALM groups) with the use of a two-sided log-rank
test. Hazard ratios (HRs) for the BMD groups
2.5< T-score<1.0 and T-score<2.5 (or ALM groups,
2.0< T-score<1.0 and T-score<2.0) as compared with
the ideal BMD (or ALM) group (T-score>1.0), and corre-
sponding 95% conﬁdence intervals (95% CI) were estimated
with the use of Cox proportional hazards models. Survival
curves were estimated using Kaplan–Meier product-limit
method.We assessed a pre-speciﬁed set of baseline character-
istics for their relevance as prognostic factors for overall
survival that included factors related to anthropometry, mobil-
ity, smoking practices, alcohol use, medication use, disease
states, and socio-economic status, as described previously
and listed in Table 1. Using Cox proportional hazardsmodelling
with age as the time variable and BMD or ALM status as the
exposure of interest, weperformed bivariate analysis of overall
survival. Mobility and polypharmacy were considered as ordi-
nal variables in the models. Baseline characteristics signiﬁcant
at a 0.1 level were used to construct the multivariable models.
A backward elimination process with a 0.05 type I error was
implemented to identify the ﬁnal models. Estimated HR and
two-sided 95% CI and P values were calculated for relevant
prognostic factors. Finally, the three BMD groups and the three
ALM groups were tested in the models simultaneously as
exposures. The statistical software package SPSS 22.0 (SPSS
Inc., Chicago, IL, USA) was used for data analysis.
Sensitivity analysis
Hazard ratios were re-analysed after excluding women whose
ALM values were derived by doubling measurements for one
side of their body. Thus, 114 were excluded because of unilat-
eral prosthesis or a body size that was too large to be fully
accommodated in the DXA scan ﬁeld.
Results
Characteristics
Subject characteristics are shown in Table 1, for the whole
group and by categories of BMD and ALM. During 6712
person-years of follow-up, 190 women died. When consider-
ing BMD, mortality was greatest in the osteoporosis category
and for ALM, mortality was greatest in the low category.
There was a pattern of increasing age, and decreasing weight,
height and body mass index (BMI) across categories of
diminishing BMD and ALM. Women with osteoporosis were
less likely to be active and more likely to avoid alcohol,
whereas those with normal BMD were less likely to have
cardiovascular disease, malignancies, and ‘other’ disorders.
Those with low ALM were more likely to be inactive, use
three or more medications, and have endocrine, gastrointes-
tinal, or ‘other’ disorders.
Bone mineral density as the exposure of interest
Bivariate analysis identiﬁed the following as statistically sig-
niﬁcant factors: height (HR 0.97, 95%CI 0.95, 0.99), currently
smoke (HR 1.61, 95%CI 0.99, 2.56), ever smoke (HR 1.49,
95%CI 1.10, 2.04), poor mobility (HR 1.76, 95% CI 1.40,
2.07), neurological disorders (HR 1.92, 95%CI 1.15, 3.19),
polypharmacy (HR 1.15, 95%CI 1.09, 1.21), cardiovascular
disease (HR 1.42, 95%CI 1.05, 1.92), endocrine disorders
(HR 1.67, 95%CI 1.17, 2.37), and gastrointestinal disorders
(HR 1.70, 95%CI 1.25, 2.30). No associations were observed
for the other variables tested, including weight and BMI.
Compared with women with ideal BMD, mortality risk
was 1.90-fold greater for those with osteopenia (HR 1.90,
95%CI 1.20, 3.01; P = 0.006) and 3.43-fold greater for those
with osteoporosis (HR 3.43, 95%CI 2.14, 5.48; P< 0.001)
(Figure 1). The multivariable model showed that mortality
risks were 1.77-fold and 2.61-fold greater for those with
osteopenia and osteoporosis, respectively, and the relation-
ships were independent of smoking, polypharmacy, and
mobility, which were also identiﬁed as signiﬁcant predictors
in the model (Table 2). Height, neurological disorders,
cardiovascular disease, and endocrine and gastrointestinal
disorders did not contribute to the ﬁnal multivariable model.
Appendicular lean mass as the exposure of interest
Bivariate analysis identiﬁed the following as statistically
signiﬁcant factors: height (HR 0.96, 95%CI 0.94, 0.99),
currently smoke (HR 1.67, 95%CI 1.03, 2.70), ever smoke
(HR 1.43, 95%CI 1.05, 1.96), poor mobility (HR 1.28, 95% CI
1.02, 1.59), polypharmacy (HR 1.14, 95%CI 1.08, 1.20), cardio-
vascular disease (HR 1.51, 95%CI 1.12, 2.04), endocrine
disorder (HR 1.68, 95%CI 1.18, 2.38), gastrointestinal
disorders (HR 1.68, 95%CI 1.23, 2.29), and malignancy (HR
1.53, 95%CI 1.06, 2.22). No associations were observed for
the other variables tested, including weight and BMI.
Compared with women with high ALM, mortality risk was
1.51-fold greater for those with medium ALM (HR 1.51,
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95%CI 1.08, 2.11; p = 0.017) and 2.28-fold greater for those
with low ALM (HR 2.28, 95%CI 1.56, 3.33; p< 0.001)
(Figure 2). In the multivariable model, mortality risks were
1.36-fold and 1.65-fold greater for those with medium and
low ALM, respectively, and the relationships were
independent of smoking, polypharmacy, and mobility, which
were also identiﬁed as signiﬁcant predictors in the model
(Table 2). Height, smoking, cardiovascular disease, endocrine
and gastrointestinal disorders, and malignancy did not
contribute to the ﬁnal multivariable model.
Figure 1 Observed cumulative survival functions for bone mineral den-
sity status. Ideal bone mineral density (BMD) (T-score>1.0);
osteopenia (T-score 2.5 to 1.0); and osteoporosis (T-score<2.5).
Table 2 Multivariable models for evaluating mortality risk according to bone mineral density status (Models 1 and 2), appendicular lean mass status
(Models 3 and 4), and both bone mineral density and appendicular lean mass (Models 5 and 6)
Model Factor HR Lower 95%CI Upper 95%CI
Model 1 Ideal BMD 1.00 — —
Osteopenia 1.90 1.20 3.01
Osteoporosis 3.43 2.14 5.48
Model 2 Ideal BMD 1.00 — —
Osteopenia 1.77 1.11 2.81
Osteoporosis 2.61 1.60 4.24
Smoking (yes) 1.96 1.20 3.18
Polypharmacy (yes) 1.11 1.05 1.17
Poor mobility (yes) 1.59 1.30 1.96
Model 3 ALM T-score >1.0 1.00 — —
ALM T-score <2.0 to 1.0 1.51 1.08 2.11
ALM T-score <2.0 2.28 1.56 3.33
Model 4 ALM T-score >1.0 1.00 — —
ALM T-score <2.0 to 1.0 1.36 0.97 1.91
ALM T-score <2.0 1.65 1.11 2.45
Smoking (yes) 1.98 1.22 3.22
Polypharmacy (yes) 1.10 1.04 1.16
Poor mobility (yes) 1.70 1.39 2.08
Model 5 Ideal BMD 1.00 — —
Osteopenia 1.74 1.09 2.78
Osteoporosis 2.82 1.70 4.70
ALM T-score >1.0 1.00 — —
ALM T-score <2.0 to 1.0 1.25 0.89 1.78
ALM T-score <2.0 1.52 1.00 2.31
Model 6 Ideal BMD 1.00 — —
Osteopenia 1.68 1.05 2.69
Osteoporosis 2.37 1.41 3.98
ALM T-score >1.0 1.00 — —
ALM T-score <2.0 to 1.0 1.19 0.84 1.68
ALM T-score <2.0 1.25 0.82 1.90
Smoking (yes) 1.97 1.21 3.20
Polypharmacy (yes) 1.11 1.05 1.17
Poor mobility (yes) 1.57 1.28 1.93
ALM, appendicular lean mass; BMD, bone mineral density; CI, conﬁdence interval; HR, hazard ratio.
Figure 2 Observed cumulative survival functions for appendicular lean
mass (ALM) status. High ALM (T-score>1.0; medium (T-score 2.0
to 1.0); and low ALM (T-score<2.0).
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Bone mineral density and appendicular lean mass
as the simultaneous exposures of interest
Bone mineral density and ALM were positively correlated
(r = 0.49, P< 0.001), and this association persisted after
adjusting for age. When BMD and ALM were tested together
in the models, BMD remained a predictor of mortality, and
low ALM had borderline signiﬁcance (P = 0.051), which was
further attenuated after adjusting the model for smoking,
polypharmacy, and mobility (Table 2). The data did not
support a bone-muscle interaction in predicting mortality as
the BMD–ALM interaction term was not signiﬁcant in this
multivariable model (P = 0.263).
Sensitivity analysis
The sensitivity analysis, that involved 704 women for whom
there were no exclusions for ALM, also identiﬁed ALM as a
predictor of mortality. In this group, compared with women
with high ALM, mortality risk was 1.42-fold greater for those
with medium ALM (HR 1.42, 95%CI 1.00, 2.02; P = 0.052) and
2.38-fold greater for those with low ALM (HR 2.38, 95%CI
1.59, 3.56; P< 0.001).
Discussion
We report that measures of both diminished bone mass and
lean mass were markers for increased mortality risk. When
considered in conjunction, mortality risk was associated with
declining BMD and this was exacerbated by low ALM. The
confounding effects of age were accounted for by using age
as the time variable.
In the early 1990s, data from the Study of Osteoporotic
Fractures in the USA revealed that women with low BMD at
the proximal radius had higher mortality.8 Subsequent stud-
ies conﬁrmed this ﬁnding using BMD at the calcaneus for
men and women from Sweden9 and BMD at the hip for
men from the UK.10 A later prospective study from the Study
of Osteoporotic Fractures reported that the rate of bone loss
at the hip for women was prognostic for increased mortality,
and that the relationship was independent of baseline
BMD.11 Higher rates of bone loss may be a marker for frailty
associated with systemic disease, drug exposures, or immo-
bility, which could also impact on skeletal muscle.
While muscle weakness is recognized as a risk factor for
mortality,5–7 less is known about the risk associated with
diminished muscle mass. In a study of healthy older Chilean
people, those in the lowest quartile of DXA-derived ALM
had higher mortality during follow-up; this association was
not evident for total lean mass.17 Using muscle mass
estimated by BIA, data from the US National Health and
Nutrition Examination Survey III revealed that low muscle
mass (normalized by height) in women aged >60 years was
associated with increased mortality risk over a median period
of 14.3 years, such that the adjusted HR for mortality was
1.32 (95%CI 1.04, 1.69); the adjusted HR for mortality among
men was not signiﬁcant.16 In another analysis using data from
the same phase of the National Health and Nutrition Exami-
nation Survey (National Health and Nutrition Examination
Survey III), but this time involving well-nourished individuals
(men aged >55 years and women aged >65 years) followed
for a median period of 13.2 years, the adjusted HR for mortal-
ity was 0.80 (95%CI 0.66, 0.97) for the highest versus the
lowest quartile of BIA-derived muscle mass normalized by
height.15 Deﬁcits in skeletal muscle mass contribute to
sarcopenia, a condition that also involves loss of muscle
quality and performance.30 In the Health, Ageing, and Body
Composition study of older participants from the USA, the
strong inverse association between muscle strength and mor-
tality was not attenuated by ALM, suggesting that muscle
strength is better than muscle mass as a marker of muscle
quality in predicting mortality.7 Nonetheless, the functional
relevance of ALM in determining limb strength and mobility
would contribute to sarcopenia being a risk factor for excess
mortality.31,32 Muscle strength and performance were not
measured in this phase of our study, which limited our ability
to further explore sarcopenia and mortality risk. However,
our observations suggest that deﬁcits in bone mass and
muscle mass are additive rather than multiplicative in
predicting mortality, and it seems likely that the co-
occurrence of osteopenia/osteoporosis and sarcopenia, in a
state described as osteosarcopenia,33 would increase the risk
for early mortality.
In conclusion, we report that musculoskeletal decline is
associated with excess mortality in a relationship that
appeared to be driven mainly by a decline in bone mass,
but with an independent contribution from low ALM. In oste-
oporosis, interventions have been shown to reduce mortal-
ity,34 and this initial observation was conﬁrmed in a meta-
analysis of randomized controlled trials35 suggesting either
a causal link between low bone mass and mortality and/or
unrecognized off-target effects of osteoporosis therapies on
mortality. The reports of sarcopenia as a predictor of mortal-
ity are consistent with our observations, but current
evidence showing a beneﬁt of intervention on mortality is
lacking.36 Low bone mass and low muscle mass may be
markers of other processes that are driving excess mortality,
such as the cumulative effect of co-morbidities that could
eventually lead to organ failure, and this could incorporate
musculoskeletal decline resulting from increased allostatic
load related to systemic inﬂammation.37,38
Major strengths of this study include, a long period of
follow-up, clinical assessments using DXA to obtain measures
of both BMD and ALM, and data linkage to the national reg-
ister that ensured complete ascertainment of deaths. We also
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acknowledge several potential weaknesses. Changes in body
composition during follow-up have not been considered,
and participants who emigrated from Australia have not been
identiﬁed. Exclusion of women with bilateral prostheses or
who were unable to provide a complete whole body DXA
scan may have introduced bias into the analyses, and the
ﬁndings may not be generalizable, as the cohort comprised
mainly (99%) White participants.27 Finally, as in all observa-
tional studies, unrecognized confounding is likely.
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